Bilcare share price & results
- Jun 2026
- Jun 2026
Pune-based pharma-packaging and clinical-trial-supplies group; parent holding company whose subsidiaries make PVC/PVDC blister films (Caprihans India) and run global clinical-trial supply-chain services (Bilcare GCS).
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1.9 | −6.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -51.0 | +17.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 1.0 | −71.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 10.55 | +1.7 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | 16.42 | −1.5 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | -0.90 | −12.3 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −22.4% 1Y
1Y: ₹108.12 on 24 Oct 2025 → ₹83.87. High ₹112.45 (27 Oct 2025), low ₹51.94 (27 Mar 2026).
- Previous close
- ₹81.5
- Market cap
- ₹223 Cr
- 52-week range
- ₹51.94 – ₹112.45
- One year
- −25.42%
- Price to earnings (TTM to Jun 2026)
- 10.26×
- Return on equity (TTM to Jun 2026)
- 10.55%
Overview
- Symbol
- NSE:BI
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Bilcare Limited does
Based on the company's own presentations, annual report and earnings calls.
Bilcare Limited is the Pune-headquartered parent of the Bilcare Group, serving the pharmaceutical industry through two operating lines run by its subsidiaries rather than directly. Caprihans India Limited (55.99%-owned) manufactures PVC and PVDC films and blister packaging materials used for primary pharmaceutical packaging. Bilcare GCS group entities based in the UK, Ireland and the USA provide clinical-trial supply-chain services -- comparator drug sourcing, development/manufacturing and primary-secondary packaging of Investigational Medicinal Products, blinding, ambient and controlled-temperature storage, and worldwide distribution through a network of depots/sites, supported by an IWRS (Interactive Web Response System). The standalone parent itself reported no in-house R&D or manufacturing expenditure in FY25 and earns brand-royalty income from group companies using the Bilcare name.
Segments
- Pharmaceutical packaging (PVC/PVDC films & blister packaging)
- Clinical trial supplies / Global Clinical Services
- Group subsidiaries
- 7 (Bilcare GCS Ltd-UK, Bilcare GCS Inc-USA, Bilcare GCS Ireland Ltd, Bilcare Inc-USA, Bilcare Pharma Solutions Ltd, Caprihans India Ltd, Bilcare Research GmbH-Germany)
- Countries with group operations
- 5 (India, UK, USA, Ireland, Germany)
- Equity stake in Caprihans India Limited (pharma-packaging subsidiary)
- 55.99%
- Registered plant/works location
- 1 (Shiroli, Rajgurunagar, Pune, India)
- New international patent applications (FY25, PPI/packaging division)
- 5
- Clinical-trial depot/site network
- Global -- expanding partnerships to cover most locations worldwide
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: −71% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 3 | 4 | 2 | 2 | 2 | 1 | 2 |
| Expenses | 5 | 4 | 6 | 3 | 3 | 3 | 9 | 3 |
| Operating profit | -3 | -1 | -2 | -1 | -1 | -2 | -8 | -1 |
| Operating margin | −98.9% | −15.5% | −38.0% | −68.1% | −73.5% | −100.6% | −665.0% | −51.0% |
| Other income | 4 | 4 | 6 | 7 | 3 | 5 | 2 | 3 |
| Interest | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | -3 | 2 | 4 | 4 | 1 | 3 | -7 | 1 |
| Tax rate | −6.9% | 23.6% | 20.4% | 20.0% | 13.3% | 5.2% | −9.2% | −14.3% |
| Net profit | -3 | 2 | 3 | 4 | 1 | 3 | -6 | 1 |
| EPS (₹ per share) | -1.09 | 0.77 | 1.43 | 1.52 | 0.44 | 1.15 | -2.70 | 0.44 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 18 | 15 | 7 |
| Expenses | 27 | 21 | 19 |
| Operating profit | -9 | -6 | -12 |
| Other income | 19 | 18 | 17 |
| Interest | 2 | 4 | 1 |
| Depreciation | 2 | 3 | 3 |
| Profit before tax | 6 | 5 | 2 |
| Net profit | 5 | 4 | 1 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 24 | 24 | 24 | 24 | 24 | 24 |
| Reserves | 20 | 387 | 392 | 396 | 430 | 397 |
| Borrowings | 690 | 8 | 10 | 11 | 672 | 12 |
| Other liabilities | 193 | 36 | 35 | 22 | 255 | 22 |
| Total liabilities | 927 | 454 | 460 | 452 | 1,380 | 455 |
| Fixed assets | 446 | 16 | 63 | 61 | 930 | 58 |
| Capital work in progress | 0 | 0 | 0 | 0 | 7 | 0 |
| Investments | 81 | 294 | 294 | 294 | 14 | 310 |
| Other assets | 400 | 144 | 104 | 98 | 429 | 88 |
| Total assets | 927 | 454 | 460 | 452 | 1,380 | 455 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | -0 | 46 | 397 | 98 | 2 | 12 |
| Cash from investing | 85 | 6 | 181 | -107 | 3 | -14 |
| Cash from financing | -82 | -55 | -571 | -1 | -4 | 0 |
| Net cash flow | 2 | -4 | 7 | -10 | 1 | -2 |
| Free cash flow | 1 | 45 | 791 | -10 | 5 | 14 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 87 | 79 | 247 | 101 | 82 | 109 |
| Inventory days | 85 | 71 | 60 | 21 | 30 | 37 |
| Days payable | 116 | 100 | 439 | 91 | 154 | 435 |
| Cash conversion cycle | 56 | 50 | -132 | 31 | -42 | -289 |
| Working capital days | -178 | -134 | -641 | 1135 | 1530 | 2541 |
| Return on capital employed | 0.3% | 1.5% | −1.4% | −2.0% | 1.6% | 0.3% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Ownership
Who owns it
Public hold 69.94% as of Jun 2026; institutions added 0.00 pts since Mar 2026.
- Promoters 30.01%
- Foreign institutions 0.04%
- Public 69.94%
Who is on the register
Named in the Jun 2026 filing
Every holder of Bilcare Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| 24.87% | unchanged | |
| 16.44% | unchanged | |
| 14.73% | unchanged | |
| 5.12% | unchanged | |
| 2.20% | unchanged | |
| 1.64% | unchanged | |
| 1.06% | unchanged | |
| 1.03% | unchanged | |
| 0.02% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Bilcare Limited
Free account: one company. Everything above stays public.
Write why you follow Bilcare Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
- EV
EVERESTOEverest Organics Ltd. - LO
LOTUSEYELotus Eye Hospital and Institute Limited - SY
SYSCHEMSyschem (India) Ltd. - GE
GENNEXGennex Laboratories Ltd - AC
ACCPLAccretion Pharmaceuticals Ltd - SA
SATKARTARSat Kartar - OX
OXYGENTAPHOXYGENTA PHARMACEUTICAL LIMITED - NE
NECLIFENectar Lifesciences Limited
Learn to analyse Bilcare Limited
Guides on how to read this kind of business and the numbers that matter.